Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 3Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 14Lymphoid 7Myeloid 6Breast 6Sarcoma 3Genitourinary 3CNS 3Thoracic 2Other solid neoplasm 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Dasatinib × Dermatologic × Clear all
NCT00597038 2013-12-16

A Phase I/II Study of Dasatinib and Dacarbazine

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
50 enrolled 11 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡